https://www.taxtmi.com/news?id=51786 Intas, via its Accord subsidiaries, acquired UDENYCA (pegfilgrastim cbqv) from Coherus, expanding its FDA approved biosimilar portfolio and consolidating global pegfilgrastim supply. Accord will commercialize UDENYCA for reducing febrile neutropenia in patients receiving myelosuppressive chemotherapy and for hematopoietic subsyndrome of acute radiation syndrome, while excluding use for progenitor cell mobilization. The product is available as autoinjector, on body injector, and prefilled syringe. The release emphasizes safety warnings, common adverse reactions, supply continuity supported by transferred Coherus personnel, and legal counsel for the transaction. en-us Thu, 07 Aug 2025 10:46:03 +0530 Thu, 07 Aug 2025 10:46:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=51786 Intas, via its Accord subsidiaries, acquired UDENYCA (pegfilgrastim cbqv) from Coherus, expanding its FDA approved biosimilar portfolio and consolidating global pegfilgrastim supply. Accord will commercialize UDENYCA for reducing febrile neutropenia in patients receiving myelosuppressive chemotherapy and for hematopoietic subsyndrome of acute radiation syndrome, while excluding use for progenitor cell mobilization. The product is available as autoinjector, on body injector, and prefilled syringe. The release emphasizes safety warnings, common adverse reactions, supply continuity supported by transferred Coherus personnel, and legal counsel for the transaction. News - Thu, 07 Aug 2025 10:46:03 +0530 https://www.taxtmi.com/news?id=51786